Allogene Therapeutics Initiates Pivotal Phase 2 ALPHA3 Trial for Cema-Cel in Large B-Cell Lymphoma
Reuters
Aug 14
Allogene <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Initiates Pivotal Phase 2 ALPHA3 Trial for Cema-Cel in Large B-Cell Lymphoma
Allogene Therapeutics Inc., a clinical-stage biotechnology company specializing in allogeneic CAR T products, has announced updates on several key clinical trials. The pivotal Phase 2 ALPHA3 trial with Cemacabtagene Ansegedleucel (Cema-Cel) is progressing as a two-arm randomized study in first-line consolidation for large B-cell lymphoma, with more than 50 sites activated in the U.S. and Canada, and international expansion underway. A scheduled futility analysis is on track for the first half of 2026. Additionally, the company has initiated the Phase 1 RESOLUTION trial with ALLO-329 for autoimmune diseases, with proof-of-concept data expected in the first half of 2026. The Phase 1 TRAVERSE trial with ALLO-316 in renal cell carcinoma is also underway. Allogene will host a live conference call and webcast to discuss these developments and financial results, with a replay available on their website for 30 days following the event.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001737287-25-000087), on August 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.